
News|Videos|February 5, 2024
HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer
Author(s)Erika P. Hamilton, MD
Erika Hamilton, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
2
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
3
Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer
4
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
5




















































